| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/13/2006 | US20060078539 Remedies for tumor in hematopoietic organs |
| 04/13/2006 | US20060078538 Thermal surgical procedures and compositions |
| 04/13/2006 | US20060078537 Mono-and dual chemokine/cytokine constructs |
| 04/13/2006 | US20060078535 Anticancer compounds and methods |
| 04/13/2006 | US20060078506 Methods, systems and devices for noninvasive pulmonary delivery |
| 04/13/2006 | US20060078494 Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| 04/13/2006 | DE102004049479A1 Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie Protein conjugates for use in therapy, diagnosis and chromatography |
| 04/13/2006 | CA2583472A1 Hcv ns3-ns4a protease inhibition |
| 04/13/2006 | CA2583431A1 Variant amyloid protein |
| 04/13/2006 | CA2583351A1 Combination anti-viral compositions comprising castanospermine and methods of use |
| 04/13/2006 | CA2582974A1 Cosmetic neurotoxin compositions comprising a botulinum toxin component and methods |
| 04/13/2006 | CA2582908A1 Macrocyclic sh2 domain binding inhibitors |
| 04/13/2006 | CA2582607A1 Compositions and methods for inducing melanogenesis in a subject |
| 04/13/2006 | CA2582567A1 Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds |
| 04/13/2006 | CA2582318A1 Globin digest containing, yeast-fermented beverages |
| 04/13/2006 | CA2582095A1 Inhibitors of hepatitis c virus |
| 04/13/2006 | CA2582022A1 Methods for the administration of iloperidone |
| 04/13/2006 | CA2581896A1 Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis |
| 04/13/2006 | CA2581798A1 A pharmaceutical formulation comprising crystalline insulin and dissolved insulin |
| 04/13/2006 | CA2581564A1 Compounds that modulate trh actions |
| 04/13/2006 | CA2581554A1 Hepatitis c virus replication system |
| 04/13/2006 | CA2581051A1 Pulmonary administration of an antithrombotic compound |
| 04/13/2006 | CA2581048A1 Use of pregnancy specific glycoprotein for maturation of oocytes |
| 04/13/2006 | CA2580426A1 Deglycosylated and desialidated long pentraxin ptx3 |
| 04/13/2006 | CA2578573A1 Use of il-17- for maturation of oocytes |
| 04/13/2006 | CA2576293A1 Agents capable of downregulating an msf-a-dependent hif-1alpha and use thereof in cancer treatment |
| 04/12/2006 | EP1645635A2 Replication defective recombinant retroviruses expressing a palliative |
| 04/12/2006 | EP1645634A2 Transgenic animal models for cardiac hypertrophy and uses thereof |
| 04/12/2006 | EP1645631A2 Neisseria antigens and compositions |
| 04/12/2006 | EP1645566A2 Analogs of parathyroid hormone |
| 04/12/2006 | EP1645565A1 Deuterated cyclosporine analogs and their use as immunomodulating agents |
| 04/12/2006 | EP1645282A1 Use of fibrinolytic metalloproteinases for treating blood clots |
| 04/12/2006 | EP1645279A1 Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections |
| 04/12/2006 | EP1645278A2 Use of aliphatic polyamines for reducing oxalate |
| 04/12/2006 | EP1645198A1 Process for producing liquid formulation containing raw yeast and liquid formulation |
| 04/12/2006 | EP1644729A2 Anti-cd74 immunoconjugates and methods |
| 04/12/2006 | EP1644509A1 Use of fak-related non-kinase in the manufacture of a medicament for the inhibition of stenosis and restenosis |
| 04/12/2006 | EP1644504A1 FACTOR VII OR VIIa GLA DOMAIN VARIANTS |
| 04/12/2006 | EP1644501A1 Ssx-2 peptides presented by hla class ii molucules |
| 04/12/2006 | EP1644498A2 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 04/12/2006 | EP1644493A1 Regulation of a kinase, 'regulated in copd kinase' (rc kinase) |
| 04/12/2006 | EP1644487A1 Regulatory t-cells containing galectins for the therapy and diagnosis of diseases |
| 04/12/2006 | EP1644411A2 Stabilised insulin compositions |
| 04/12/2006 | EP1644410A1 Sushi peptide multimer |
| 04/12/2006 | EP1644409A1 Complement depletion using recombinant human c3-derivatives |
| 04/12/2006 | EP1644408A1 Eimeria tenella antigen for immunotherapy of coccidiosis |
| 04/12/2006 | EP1644406A2 Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 04/12/2006 | EP1644403A2 Cytotoxic depsipeptides |
| 04/12/2006 | EP1644402A1 Arginine/lysine-enriched peptides |
| 04/12/2006 | EP1644382A2 Cross-linked glycopeptide-cephalosporin antibiotics |
| 04/12/2006 | EP1644032A1 Inhibitors of cell migration |
| 04/12/2006 | EP1644031A1 Inhibitors of the leukocyte prommp-9/beta(2) integrin complex |
| 04/12/2006 | EP1644030A1 Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
| 04/12/2006 | EP1644029A2 Use of dg008, dg065, dg210 or dg 239 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 04/12/2006 | EP1644028A2 Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections |
| 04/12/2006 | EP1644027A1 Use of pleiotrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 04/12/2006 | EP1644026A2 Sigma ligands for neuronal regeneration and functional recovery |
| 04/12/2006 | EP1644025A1 Water-soluble shps as novel alkylating agents |
| 04/12/2006 | EP1644024A2 Antimicrobial flush solutions |
| 04/12/2006 | EP1644023A2 Melanocortin recptor 4(mc4) agonists and their uses |
| 04/12/2006 | EP1644022A1 Uses of melanocortin-3 receptor (mc3r) agonist peptides |
| 04/12/2006 | EP1644021A2 Methods and compositions for the treatment of gastrointestinal disorders |
| 04/12/2006 | EP1644020A2 Lyase treatment for p. carinii |
| 04/12/2006 | EP1644019A1 Abuse resistant amphetamine compounds |
| 04/12/2006 | EP1644018A2 Soluble clca-1 and antagonists to clca-1 |
| 04/12/2006 | EP1644017A2 Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells |
| 04/12/2006 | EP1644011A1 Conditioned matrix compositions for tissue restoration |
| 04/12/2006 | EP1643978A1 Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
| 04/12/2006 | EP1643977A2 Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form |
| 04/12/2006 | EP1643970A2 Compositions and methods for enhanced mucosal delivery of growth hormone |
| 04/12/2006 | EP1643959A2 Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment |
| 04/12/2006 | EP1643946A2 Compositions for and methods for treating hiv |
| 04/12/2006 | EP1643865A1 Nutritional compositions and use thereof |
| 04/12/2006 | EP1643863A2 Foods, beverages, condiments, spices and salad dressings with specialized supplements |
| 04/12/2006 | EP1578196A4 Mda-7 and free radicals in the treatment of cancer |
| 04/12/2006 | EP1539261B1 Metal implant coated under reduced oxygen concentration with osteoinductive protein |
| 04/12/2006 | EP1485346A4 Novel positively charged lipids and liposomes comprising the positively charged lipids |
| 04/12/2006 | EP1346230B1 Screening method based on tsap6 binding partners |
| 04/12/2006 | EP1334174B1 Paramyxovirus vector for gene transfer to the cardiovascular system |
| 04/12/2006 | EP1331940B1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 04/12/2006 | EP1299416B1 Antifungal and/or antibacterial peptides, preparation methods and composition containing same |
| 04/12/2006 | EP1297116B1 Method for isolating and purifying a protein |
| 04/12/2006 | EP1294394B1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR Xa INHIBITOR |
| 04/12/2006 | EP1262065B1 Method and system for providing a customized media list |
| 04/12/2006 | EP1250435B1 Human neurexin-like proteins and polynucleotides encoding the same |
| 04/12/2006 | EP1207873A4 Methods of inhibiting osteoclast activity |
| 04/12/2006 | EP1194156B1 Dietary supplement for treating malignancies and viral infections and improving immune function |
| 04/12/2006 | EP1192247B1 Sphingosine kinase enzyme |
| 04/12/2006 | EP1152749B1 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| 04/12/2006 | EP1144435B1 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 04/12/2006 | EP1118659B1 Expression systems for functional nucleic acid expression |
| 04/12/2006 | EP1100821B1 Anti-inflammatory compounds derived from lipocortin-1 |
| 04/12/2006 | EP1087981B1 Prenyl transferase inhibitors |
| 04/12/2006 | EP1005356B1 Novel antibacterial agents |
| 04/12/2006 | EP0985046B1 Recombinant poxvirus incapable of expressing a41l gene, coding for a soluble protein that binds chemokines |
| 04/12/2006 | EP0972042B1 Polypeptide expressed in the horny layer of epidermis and use thereof |
| 04/12/2006 | EP0938328B1 Method of inhibiting fibrosis with a somatostatin agonist |
| 04/12/2006 | EP0861319B1 Immunity against actinobacillus pleuropneumoniae's rtx toxins apx |
| 04/12/2006 | EP0843726B1 Opioid antagonists and methods of their use |
| 04/12/2006 | CN1759176A Diagnosis and treatment of multiple sulfatase deficiency andother sulfatase deficiencies using a formylglycine generating enzyme (FGE) |